
KRRO Stock Forecast & Price Target
KRRO Analyst Ratings
Bulls say
Korro Bio is a promising biopharmaceutical company with a unique approach to genetic medicines using RNA editing technology. Their focus on stabilizing glutamine synthetase (GS) has solid human genetic evidence to support its effectiveness in reducing ammonia levels, which is a shared driver of disease in UCD and HE patients. With a strong preclinical data package, multiple established regulatory paths, and a risk-mitigated pipeline, Korro Bio has the potential to achieve meaningful benefits and become a leader in the field. Despite being a development stage company, we estimate a 20% probability of approval and $2B peak sales for KRRO-121, supporting a 12-month price target of $20 per share. However, we acknowledge the need for additional funding in the future, which may involve dilution or restrictive covenants.
Bears say
Korro Bio is a clinical-stage biopharmaceutical company with a focus on developing genetic medicines through RNA editing technology. While the company has intriguing prospects in the rare disease market with its experimental medication, KRRO-121, there are significant investment concerns. The company has not yet proved its ability to successfully develop and commercialize a product, and faces fierce competition in the biotechnology and pharmaceutical industries. Additionally, the company's genetic editing approach may face challenges from regulators and patent infringement suits, which could lead to significant legal expenses. Overall, there are numerous risks that could impact the success and profitability of Korro Bio, which warrants a negative outlook from a financial analyst.
This aggregate rating is based on analysts' research of Frequency Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
KRRO Analyst Forecast & Price Prediction
Start investing in KRRO
Order type
Buy in
Order amount
Est. shares
0 shares